US 12,358,900 B2
Acid addition salts of benzimidazole derivative
Eun Sun Kim, Gangwon-do (KR); Min Kyoung Lee, Seoul (KR); Sung Ah Lee, Gyeonggi-do (KR); Kwang Do Choi, Gyeonggi-do (KR); Jae Sun Kim, Gyeonggi-do (KR); and Hyung Chul Yoo, Gyeonggi-do (KR)
Assigned to HK INNO.N CORPORATION, Chungcheongbuk-do (KR)
Filed by HK INNO.N CORPORATION, Chungcheongbuk-do (KR)
Filed on Jan. 16, 2024, as Appl. No. 18/413,666.
Application 18/413,666 is a continuation of application No. 17/990,806, filed on Nov. 21, 2022, granted, now 11,912,690.
Application 17/990,806 is a continuation of application No. 16/334,427, granted, now 11,535,610, issued on Dec. 27, 2022, previously published as PCT/KR2017/010332, filed on Sep. 20, 2017.
Claims priority of application No. 10-2016-0120996 (KR), filed on Sep. 21, 2016.
Prior Publication US 2024/0150331 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 405/12 (2006.01); C07D 235/06 (2006.01)
CPC C07D 405/12 (2013.01) [C07D 235/06 (2013.01)] 20 Claims
 
1. A method of treating a disease mediated by an acid pump antagonistic activity in a patient in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a pidolate salt of a compound represented by Formula 1, wherein the disease is selected from the group consisting of gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, an ulcer induced by NSAID, gastritis, Helicobacter pylori infection, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, nonerosive reflux disease (NERD), visceral pain, purosis, nausea, esophagitis, dysphagia, salivation, an airway lesion, and asthma:

OG Complex Work Unit Chemistry